{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:32:40Z","timestamp":1793514760545,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40744-024-00743-5","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:12:40Z","timestamp":1739272360000},"page":"315-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis"],"prefix":"10.1007","volume":"12","author":[{"given":"Antoni","family":"Sicras-Mainar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Sorio-Vilela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sacrest-Soy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Sicras-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Villoro-Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rebollo-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2231-4228","authenticated-orcid":false,"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"1","key":"743_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010074422268","volume":"2","author":"LG Raisz","year":"2001","unstructured":"Raisz LG. Pathogenesis of postmenopausal osteoporosis. Rev Endocr Metab Disord. 2001;2(1):5\u201312.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"743_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16(1):82\u201382.","journal-title":"Arch Osteoporos"},{"key":"743_CR3","unstructured":"International Osteoporosis Federation. About osteoporosis. https:\/\/www.osteoporosis.foundation\/health-professionals\/about-osteoporosis."},{"issue":"5","key":"743_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513\u2013513.","journal-title":"JAMA"},{"issue":"12","key":"743_CR5","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00198-023-06870-z","volume":"34","author":"JA Kanis","year":"2023","unstructured":"Kanis JA, et al. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporos Int. 2023;34(12):2027\u201345.","journal-title":"Osteoporos Int"},{"issue":"11","key":"743_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00198-003-1460-x","volume":"14","author":"C Col\u00f3n-Emeric","year":"2003","unstructured":"Col\u00f3n-Emeric C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003;14(11):879\u201383.","journal-title":"Osteoporos Int"},{"issue":"5 Suppl 51","key":"743_CR7","first-page":"S125","volume":"26","author":"GG Teng","year":"2008","unstructured":"Teng GG, Curtis JR, Saag KG. Mortality and osteoporotic fractures: is the link causal, and is it modifiable? Clin Exp Rheumatol. 2008;26(5 Suppl 51):S125\u201337.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"743_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstr\u00f6m","year":"2020","unstructured":"Borgstr\u00f6m F, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020;15(1):59\u201359.","journal-title":"Arch Osteoporos"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.bone.2018.12.016","volume":"120","author":"B Abrahamsen","year":"2019","unstructured":"Abrahamsen B, Skj\u00f8dt MK, Vestergaard P. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. Bone. 2019;120:476\u201381.","journal-title":"Bone"},{"issue":"7","key":"743_CR10","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.2106\/JBJS.L.01781","volume":"96","author":"A Balasubramanian","year":"2014","unstructured":"Balasubramanian A, et al. Declining rates of osteoporosis management following fragility fractures in the US, 2000 through 2009. J Bone Jt Surg. 2014;96(7):e52\u2013e52.","journal-title":"J Bone Jt Surg"},{"issue":"1","key":"743_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/00325481.2015.993278","volume":"127","author":"VS Lagari","year":"2015","unstructured":"Lagari VS, McAninch E, Baim S. Considerations regarding adherence of anti-osteoporosis therapy. Postgrad Med. 2015;127(1):92\u20138.","journal-title":"Postgrad Med"},{"issue":"6","key":"743_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/08952841.2018.1529473","volume":"31","author":"B Mugnier","year":"2019","unstructured":"Mugnier B, et al. Clinical effectiveness of osteoporosis treatment in older patients: a fracture liaison service-based prospective study. J Women Aging. 2019;31(6):553\u201365.","journal-title":"J Women Aging"},{"issue":"3","key":"743_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1185\/03007990903512321","volume":"26","author":"P Sambrook","year":"2010","unstructured":"Sambrook P, Cranney A, Adachi JD. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Curr Med Res Opin. 2010;26(3):599\u2013604.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"743_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11914-019-00544-8","volume":"17","author":"PJ Mitchell","year":"2019","unstructured":"Mitchell PJ, et al. Quality improvement initiatives in fragility fracture care and prevention. Curr Osteoporos Rep. 2019;17(6):510\u201320.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"743_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11914-020-00644-w","volume":"19","author":"KE \u00c5kesson","year":"2021","unstructured":"\u00c5kesson KE, McGuigan FEA. Closing the osteoporosis care gap. Curr Osteoporos Rep. 2021;19(1):58\u201365.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"743_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3\u201344.","journal-title":"Osteoporos Int"},{"key":"743_CR17","unstructured":"European Medicines Agency. BIG-PAC Database. HMA-EMA Catalogues of real-world data sources and studies. 2024. https:\/\/catalogues.ema.europa.eu\/node\/4136\/administrative-details"},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","volume":"22","author":"A Sicras-Mainar","year":"2019","unstructured":"Sicras-Mainar A, et al. PMU146 validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real word evidence). Value Health. 2019;22:S734\u2013S734.","journal-title":"Value Health"},{"issue":"1","key":"743_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","volume":"75","author":"A Sicras-Mainar","year":"2022","unstructured":"Sicras-Mainar A, et al. Epidemiolog\u00eda y tratamiento de la insuficiencia cardiaca en Espa\u00f1a: estudio PATHWAYS-HF. Rev Esp Cardiol. 2022;75(1):31\u20138.","journal-title":"Rev Esp Cardiol"},{"key":"743_CR20","unstructured":"World Health Organization. Anatomical therapeutic chemical (ATC) classification. https:\/\/www.whocc.no\/atc\/structure_and_principles\/."},{"key":"743_CR21","unstructured":"Agenicia Estatal. Bolet\u00edn Oficial del Estado. Ley Org\u00e1nica 3\/2018, de 5 de diciembre, de Protecci\u00f3n de Datos Personales y garant\u00eda de los derechos digitales. https:\/\/www.boe.es\/eli\/es\/lo\/2018\/12\/05\/3\/con. 2018."},{"issue":"1","key":"743_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","volume":"50","author":"JF Steiner","year":"1997","unstructured":"Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105\u201316.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"743_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"743_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11657-022-01124-7","volume":"17","author":"D Martinez-Laguna","year":"2022","unstructured":"Martinez-Laguna D, et al. Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study. Arch Osteoporos. 2022;17(1):93.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"743_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, et al. The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. 2021;32(2):251\u20139.","journal-title":"Osteoporos Int"},{"key":"743_CR26","doi-asserted-by":"crossref","unstructured":"Gonzalez-Macias J, et al. Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). Rev Clin Esp (Barc). 2015;215(9):515\u201326.","DOI":"10.1016\/j.rceng.2015.08.005"},{"issue":"4","key":"743_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, et al. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4): e027049.","journal-title":"BMJ Open"},{"issue":"11","key":"743_CR28","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020;31(11):2093\u2013102.","journal-title":"Osteoporos Int"},{"issue":"10","key":"743_CR29","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00198-017-4144-7","volume":"28","author":"C Reyes","year":"2017","unstructured":"Reyes C, et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017;28(10):2997\u20133004.","journal-title":"Osteoporos Int"},{"issue":"3","key":"743_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","volume":"31","author":"J Morley","year":"2020","unstructured":"Morley J, et al. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int. 2020;31(3):533\u201345.","journal-title":"Osteoporos Int"},{"issue":"10","key":"743_CR31","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016;27(10):2967\u201378.","journal-title":"Osteoporos Int"},{"issue":"10","key":"743_CR32","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, et al. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26(10):2401\u201311.","journal-title":"Osteoporos Int"},{"issue":"1","key":"743_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11657-023-01210-4","volume":"18","author":"AB Pedersen","year":"2023","unstructured":"Pedersen AB, et al. Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study. Arch Osteoporos. 2023;18(1):19.","journal-title":"Arch Osteoporos"},{"issue":"7","key":"743_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.rce.2021.12.007","volume":"222","author":"JA Riancho","year":"2022","unstructured":"Riancho JA, et al. Resumen ejecutivo de las gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis posmenop\u00e1usica, glucocorticoidea y del var\u00f3n (actualizaci\u00f3n 2022). Sociedad Espa\u00f1ola de Investigaci\u00f3n \u00d3sea y del Metabolismo Mineral (SEIOMM). Rev Clin Esp. 2022;222(7):432\u20139.","journal-title":"Rev Clin Esp"},{"issue":"6","key":"743_CR35","first-page":"373","volume":"59","author":"I Etxebarria-Foronda","year":"2015","unstructured":"Etxebarria-Foronda I, et al. SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update. Rev Esp Cir Ortop Traumatol. 2015;59(6):373\u201393.","journal-title":"Rev Esp Cir Ortop Traumatol"},{"issue":"1","key":"743_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11657-021-00969-8","volume":"17","author":"C Willers","year":"2022","unstructured":"Willers C, et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23.","journal-title":"Arch Osteoporos"},{"issue":"4","key":"743_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.radi.2018.05.003","volume":"24","author":"E Eccles","year":"2018","unstructured":"Eccles E, Thompson JD, Roddam H. An evaluation of Fracture Liaison Services in the detection and management of osteoporotic fragility fractures: a narrative review. Radiography (Lond). 2018;24(4):392\u20135.","journal-title":"Radiography (Lond)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00743-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:05:17Z","timestamp":1742313917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00743-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00743-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antoni Sicras-Mainar, Aram Sicras-Navarro, and Renata Villoro-Vald\u00e9s worked at Atrys Health at the time of the study. They are no longer affiliated with their affiliation at the time of study. Francesc Sorio-Vilela worked at Amgen (he is no longer affiliated with his affiliation at the time of study). Sonia Gatell and Marta Sacrest-Soy are employees of Amgen, and Elena Rebollo-G\u00f3mez and Ignacio Hern\u00e1ndez are employees of Atrys Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee Comit\u00e9 de \u00c9tica de Investigaci\u00f3n con Medicamentos (CEIm) Consorci Sanitari de Terrassa and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}